Bottom line: despite the risks of obesity, the FDA is concerned about the possible safety risks of a drug that people might take every day for the rest of their lives.
Back to basics! More activity; more sleep; more veggies; less sugar; less prepared food…
From the Wall Street Journal:
And Orexigen’s Contrave Makes 3: FDA Rejects (Another) Diet Drug
The FDA said it wouldn’t consider approving the experimental weight-loss drug Contrave without another clinical trial, says the drug’s developer, Orexigen Therapeutics.
Such a trial — to demonstrate that the drug doesn’t raise the risk of heart attack or stroke — would likely be lengthy and expensive. The decision comes after an FDA advisory panel voted in December to recommend approval of the drug.
Health Blog readers, given all this, when do you expect a new weight-loss drug to hit the U.S. market?